Court Rules in Amgen's Favor in TKT Litigation; Affirms Validity of EPO Patents
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Oct. 15, 2004--Amgen, Inc.
(NASDAQ:AMGN), the world's largest biotechnology company, today
announced that Judge William G. Young of the U.S. District Court of
Massachusetts in Boston ruled in its favor in the patent litigation
suit against Transkaryotic Therapies Inc. ("TKT") and Aventis
Pharmaceuticals Inc. The Court found Amgen's patent claims valid and
infringed by TKT and Aventis.
Today's decision addressed the issues remanded to the District
Court from the U.S. Court of Appeals for the Federal Circuit and
focused on the validity of two product patents on erythropoietin and
the validity and infringement of two patents with claims to production
of erythropoietin. The District Court found all the patents valid and
the process patents infringed. The result of this decision, coupled
with earlier decisions, is that four Amgen patents on erythropoietin
have been held valid, enforceable, and infringed.
This ruling confirms the strength of Amgen's patent rights on
erythropoietin and protects Amgen's breakthrough inventions that have
helped over a million people worldwide. Amgen will continue to
vigorously enforce its intellectual property.
Amgen is a global biotechnology company that discovers, develops,
manufactures and markets important human therapeutics based on
advances in cellular and molecular biology.
CONTACT: Amgen, Thousand Oaks
Christine Cassiano, 805-447-4587 (media)
Laura Biswas, 805-447-1060 (investors)